Source: http://www.emcdda.europa.eu/stats12
Timestamp: 2017-01-21 09:11:55
Document Index: 640539816

Matched Legal Cases: ['art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0', 'art0']

EMCDDA | ARCHIVED DATA — Statistical bulletin 2012
Home Data Countries Topics (A–Z) Our activities Best practice Publications News Events About EMCDDA > Data > Statistical archive > Statistical bulletin 2012
BStatistical bulletin 2012 [ARCHIVE]
Data home General population surveys Problem drug use Treatment demand Drug-related deaths Infectious diseases Youth and schools Drug law offences Drug use in prison Health and social responses Drug seizures Price and purity Data: statistical bulletin 2012 [ARCHIVE]
Please note: this is a data archive. For the most recent data and statistics, please see the the main Data and statistics section of our website. The interactive version of the Statistical bulletin should appear in your browser window in a matter of seconds. If, however, you continue to see either this text and/or a loading status message, the interactive version may not be functioning correctly. This could be due to your browser's settings, the version of browser you're using, or a technical error on our side. Please begin by consulting the Explanatory notes and help page but feel free to contact us for further assistance (online[a]emcdda.europa.eu — dont't forget to replace '[a]' with '@' before sending the message).
Please note you can also access all statistical elements and data on the listing of all statistics page.
The Statistical bulletin is published yearly by the EMCDDA and provides access to the most recent statistical data relating to the drugs situation in Europe. Statistics are organised by category. In addition to the statistical tables and graphs, an overview of the data is provided for each category. Data: statistical bulletin 2012 [ARCHIVE]
Please note: this is a data archive. For the most recent data and statistics, please see the the main Data and statistics section of our website. The Statistical bulletin is published yearly by the EMCDDA and consists of over 400 tables and 100 graphs of the most recent available data on the drug situation in Europe, all available to view interactively on screen and download in Excel format.
The information covers a broad range of areas including the most recent estimates of treatment and prevalence, information on focused studies of drug related infectious diseases and of problem drug use, levels of drug related deaths, drug related crime in the form of drug seizures, types of offence, price, purity and use in prison, and country responses to the drug situation in Europe.
The Statistical bulletin is the result of close interaction between focal points and experts at the country level, and the EMCDDA at the European level. A highlight this year is the inclusion of data from the most recent European School Survey Project on Alcohol and Other Drugs (ESPAD) which provides an important insight into drug use at school level across Europe.
The information provided here may be freely reused, provided it is reproduced accurately, not presented in a misleading way and that all sources are acknowledged (see the help page for full details).
Please note: this is a data archive. For the most recent data and statistics, please see the the main Data and statistics section of our website. To get started, select one of the categories below.
Prevalence and population estimates
Treatment demand and health and social responses
Crime, seizures and market data
Please note: this is a data archive. For the most recent data and statistics, please see the the main Data and statistics section of our website. Type
dlotab1
Drug law offences, 1995 to 2010
/stats12/dlotab1a
dlotab1a
Table-DLO-01-parti.xml
Number of reports of persons
/stats12/dlotab1b
dlotab1b
Table-DLO-01-partii.xml
/stats12/dlotab1c
Table-DLO-01-partiii.xml
dlotab2
Offence types in reports for drug law offences, 2009 or 2010
Number and percentage of all reports for drug law offences
/stats12/dlotab2a
dlotab2a
Table-DLO-02-parti.xml
Offence types involved in reports for drug law offences: methods of percentages calculation for drug law offences
/stats12/dlotab2b
dlotab2b
Table-DLO-02-partii.xml
dlotab3
Drug types in reports for drug law offences, 2009 or 2010
/stats12/dlotab3a
dlotab3a
Table-DLO-03-parti.xml
Drug types in reports for drug law offences
/stats12/dlotab3b
dlotab3b
Table-DLO-03-partii.xml
dlotab4
Drug law offences related to drug use or possession for use, 2003 to 2010
/stats12/dlotab4a
dlotab4a
Table-DLO-04-parti.xml
/stats12/dlotab4b
Table-DLO-04-partii.xml
dlotab5
Drug law offences related to drug supply, 2003 to 2010
/stats12/dlotab5a
dlotab5a
Table-DLO-05-parti.xml
/stats12/dlotab5b
Table-DLO-05-partii.xml
dlotab6
Cannabis-related offences, 2003 to 2010
Number and percentage of all drug law offences
/stats12/dlotab6a
dlotab6a
Table-DLO-06-parti.xml
/stats12/dlotab6b
dlotab6b
Table-DLO-06-partii.xml
dlotab7
Heroin-related offences, 2003 to 2010
/stats12/dlotab7a
dlotab7a
Table-DLO-07-parti.xml
/stats12/dlotab7b
dlotab7b
Table-DLO-07-partii.xml
dlotab8
Cocaine-related offences, 2003 to 2010
/stats12/dlotab8a
dlotab8a
Table-DLO-08-parti.xml
/stats12/dlotab8b
Table-DLO-08-partii.xml
dlotab109
Number of reports for drug law offences, 1985 to 2010
/stats12/dlotab109a
dlotab109a
Table-DLO-109-parti.xml
/stats12/dlotab109b
dlotab109b
Table-DLO-109-partii.xml
/stats12/dlotab109c
dlotab109c
Table-DLO-109-partiii.xml
dlofig1
Indexed trends in reports for drug-related offences by broad type of offence in the EU Member States, 2005–10
/stats12/dlofig1
Table-DLO-g01-parti.xml
dlofig2
Offence types in reports for drug law offences in the EU Member States, Croatia and Norway, 2009 or 2010
/stats12/dlofig2
Table-DLO-g02-parti.xml
Indexed trends in reports for drug law offences by type of drug in the EU Member States, 2005–10
/stats12/dlofig3
Table-DLO-g03-parti.xml
Indexed trends in reports for offences related to drug use or possession for use in the EU Member States, 2005–10
/stats12/dlofig4
Table-DLO-g04-parti.xml
dlofig5
Indexed trends in reports for offences related to drug supply in the EU Member States, 2005–10
/stats12/dlofig5
Table-DLO-g05-parti.xml
drdtab0
Drug-induced deaths recorded in EU Member States according to national definitions: sources and bibliographic references
/stats12/drdtab0
Table-DRD-00-part0.xml
drdtab1
Summary of characteristics of the deceased in drug-induced deaths according to national definitions
Demographic characteristics, 2010 or last year with available information
/stats12/drdtab1a
Table-DRD-01-parti.xml
Numbers of drug-induced deaths and toxicology, 2010 or last year with available information
/stats12/drdtab1b
Table-DRD-01-partii.xml
Demographic characteristics and toxicology, 1990 or earliest year with available information
/stats12/drdtab1c
Table-DRD-01-partiii.xml
drdtab2
Number of drug-induced deaths recorded in EU Member States according to national definitions
/stats12/drdtab2a
Table-DRD-02-parti.xml
Male drug-induced deaths, 1995 to 2010
/stats12/drdtab2b
Table-DRD-02-partii.xml
Female drug-induced deaths, 1995 to 2010
/stats12/drdtab2c
Table-DRD-02-partiii.xml
Total drug-induced deaths under the age of 25 years, 1995 to 2010
/stats12/drdtab2d
drdtab2d
Table-DRD-02-partiv.xml
Totals and indexes, 1995 to 2010
/stats12/drdtab2e
Table-DRD-02-partv.xml
drdtab3
Number of drug-induced deaths recorded in EU Member States and Norway according to EMCDDA standard definition 'Selection B', 1995 to 2010
/stats12/drdtab3
Table-DRD-03-part0.xml
drdtab4
Number of drug-induced deaths recorded in EU Member States according to EMCDDA standard definition 'Selection D', 1995 to 2010
/stats12/drdtab4
Table-DRD-04-part0.xml
drdtab5
Mortality due to drug-induced deaths in European countries, in all adults and adults aged 15 to 39 years (total and males)
Population mortality rates, 2010 or last year with available information
/stats12/drdtab5a
Table-DRD-05-parti.xml
Proportional mortality due to drug-induced deaths, 2009 or last year with available information.
/stats12/drdtab5b
drdtab5b
Table-DRD-05-partii.xml
Estimated mortality (numbers and population rates) due to AIDS attributable to injection drug use
/stats12/drdtab5c
Table-DRD-05-partiii.xml
drdtab106
Methodological features of drug-induced deaths reported by National Reitox Focal Points (Based on national definitions - Reitox Standard Table 5)
/stats12/drdtab106
Table-DRD-106-part0.xml
drdtab107
Total drug-induced deaths, 1985 to 2010
/stats12/drdtab107a
drdtab107a
Table-DRD-107-parti.xml
Totals and indexes, 1985 to 2010
/stats12/drdtab107b
drdtab107b
Table-DRD-107-partii.xml
drdtab108
Drug-induced deaths: Detailed qualitative national information on deaths due to specific substances in EU Member States (2011 National Reports)
/stats12/drdtab108
Table-DRD-108-part0.xml
drdfig1
Proportion of drug-induced deaths that show presence of opioids for the most recent year reported
/stats12/drdfig1
Table-DRD-g01-part0.xml
drdfig2
Proportion of drug-induced deaths occurring under the age of 25 years for the most recent year reported
/stats12/drdfig2
Table-DRD-g02-part0.xml
drdfig3
Trends in mean age of drug-induced deaths in some of the EU-15 Member States, 1990 to 2010
/stats12/drdfig3
Table-DRD-g03-part0.xml
drdfig4
Trends in mean age of drug-induced deaths in some new EU Member States, 1990 to 2010
/stats12/drdfig4
Table-DRD-g04-part0.xml
drdfig5
lndexed trends in drug-induced deaths and in the numbers of deaths occurring under the age of 25
Indexed trend in the EU-15 Member States and Norway 1990–2009
/stats12/drdfig5a
drdfig5a
Table-DRD-g05-parti.xml
Indexed trend in the new Member States, 1990–2009
/stats12/drdfig5b
drdfig5b
Table-DRD-g05-partii.xml
drdfig6
Indexed overall trends for males and females in drug-induced deaths in the EU-15 Member States and Norway, 1990 to 2009
/stats12/drdfig6
Table-DRD-g06-part0.xml
drdfig7
Mortality due to drug-induced deaths among all adults (15 to 64 years) in European countries for the most recent year reported
Mortality rates per million among all adults (15 to 64 years) due to drug-related deaths
/stats12/drdfig7a
drdfig7a
Table-DRD-g07-parti.xml
Mortality rates among all adults (15 to 64 years) due to drug-related deaths and estimated mortality rates due to HIV/AIDS attributable to injection drug use
/stats12/drdfig7b
Table-DRD-g07-partii.xml
drdfig8
Indexed long term trend in drug-induced deaths in the EU-15 Member States and Norway, 1985 to 2009
/stats12/drdfig8
Table-DRD-g08-part0.xml
drdfig9
Trends in the proportion of drug-induced deaths occurring under the age of 25 years in the Member States, 1990 to 2010 (three-year moving average)
Some EU Member States and Norway, 1990 to 2010
/stats12/drdfig9a
drdfig9a
Table-DRD-g09-parti.xml
Some EU Member States, 1990 to 2010
/stats12/drdfig9b
Table-DRD-g09-partii.xml
Some EU countries, 1990 to 2010
/stats12/drdfig9c
Table-DRD-g09-partiii.xml
drdfig10
Mean age of drug-induced deaths in EU Member States, last year with available data
/stats12/drdfig10
Table-DRD-g10-part0.xml
drdfig11
Indexed time series of patterns of drug-induced deaths in different countries (according to general temporal patterns of evolution) and in the EU as a whole
Index in some Member States, 1985 to 2010
/stats12/drdfig11a
Table-DRD-g11-parti.xml
/stats12/drdfig11b
Table-DRD-g11-partii.xml
/stats12/drdfig11c
Table-DRD-g11-partiii.xml
drdfig12
Changes in numbers and ratio of drug-induced deaths in the EU Member States, Croatia and Norway
Changes between 2000 and 2003
/stats12/drdfig12a
drdfig12a
Table-DRD-g12-parti.xml
Changes between 2003 and 2009/10
/stats12/drdfig12b
drdfig12b
Table-DRD-g12-partii.xml
drdfig13
Number of drug-induced deaths recorded in EU Member States occurring under the age of 25 according to national definitions.
EU-15 Member States and Norway 1990–2009
/stats12/drdfig13a
drdfig13a
Table-DRD-g13-parti.xml
New Member States, 1990–2009
/stats12/drdfig13b
Table-DRD-g13-partii.xml
duptab0
Prevalence of drug use among prisoners — Sources and bibliographic references
/stats12/duptab0
Table-DUP-00-parti.xml
duptab1
Prevalence of lifetime drug use among prisoners, 2000–2010
/stats12/duptab1
Table-DUP-01-parti.xml
duptab2
Prevalence of lifetime injecting drug use among prisoners, 2000–2010
/stats12/duptab2
Table-DUP-02-parti.xml
duptab3
Prevalence of drug use within prison among prisoners, 2000–2010
/stats12/duptab3
Table-DUP-03-parti.xml
duptab4
Prevalence of injecting drug use within prison among prisoners, 2000–2010
/stats12/duptab4
Table-DUP-04-parti.xml
duptab105
/stats12/duptab105
Table-DUP-105-part0.xml
School surveys: Sources
/stats12/eyetab0
Table-EYE-00-part0.xml
eyetab08
HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old
/stats12/eyetab08
Table-EYE-08-part0.xml
eyetab9
HBSC school surveys (2009/10): percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10)
/stats12/eyetab9a
Table-EYE-09-parti.xml
/stats12/eyetab9b
Table-EYE-09-partii.xml
HBSC school surveys (2009/10) percentage lifetime prevalence of cannabis use among students aged 15–16 years old HBSC school surveys (2009/10)
/stats12/eyetab9c
Table-EYE-09-partiii.xml
eyetab10
Recent school surveys (2005-2011): percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years old
/stats12/eyetab10
Table-EYE-10-part0.xml
School surveys: percentage lifetime prevalence of psychoactive substance use among students aged 15–16 years
/stats12/eyetab11
Table-EYE-11-part0.xml
eyetab20
ESPAD 2011 school surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
/stats12/eyetab20a
Table-EYE-20-parti.xml
/stats12/eyetab20b
Table-EYE-20-partii.xml
/stats12/eyetab20c
eyetab20c
Table-EYE-20-partiii.xml
eyetab21
ESPAD 2011 school surveys: lifetime (LTP), last year (LYP) and last month (LMP) prevalence of cannabis use among students 15–16 years
/stats12/eyetab21a
Table-EYE-21-parti.xml
/stats12/eyetab21b
eyetab21b
Table-EYE-21-partii.xml
/stats12/eyetab21c
Table-EYE-21-partiii.xml
eyetab22
All ESPAD School Surveys: Lifetime prevalence (percentages) of psychoactive substance use among students 15–16 years
/stats12/eyetab22a
Table-EYE-22-parti.xml
/stats12/eyetab22b
eyetab22b
Table-EYE-22-partii.xml
/stats12/eyetab22c
eyetab22c
Table-EYE-22-partiii.xml
eyetab23
All ESPAD school surveys: prevalence and patterns (percentages) of cannabis use among students 15–16 years
/stats12/eyetab23a
eyetab23a
Table-EYE-23-parti.xml
/stats12/eyetab23b
Table-EYE-23-partii.xml
/stats12/eyetab23c
Table-EYE-23-partiii.xml
eyetab30
Recent School Surveys (2003-2011): percentage lifetime prevalence of psychoactive substance use and last month prevalence of cannabis among students aged 17-18 years old
/stats12/eyetab30
Table-EYE-30-part0.xml
eyefig1
Cannabis prevalence rates, ESPAD 2011
Different patterns in trends in lifetime prevalence of cannabis use among 15- to 16-year-old school students over the five rounds of the ESPAD survey
/stats12/eyefig1a
Table-EYE-g01-parti.xml
/stats12/eyefig1b
eyefig1b
Table-EYE-g01-partii.xml
/stats12/eyefig1c
Table-EYE-g01-partiii.xml
Comparison of lifetime prevalence of cannabis use with perceived great risk (percentages), among 15/16 year olds school students in 2007/2011
/stats12/eyefig1d
Table-EYE-g01-partiv.xml
Nationwide surveys among the general population: Bibliographic references
/stats12/gpstab0
Table-GPS-00-part0.xml
gpstab1
Lifetime prevalence of drug use by age and country, most recent national general population survey available since 2000.
/stats12/gpstab1a
Table-GPS-01-parti.xml
All adults (aged 15 - 64).
/stats12/gpstab1b
gpstab1b
Table-GPS-01-partii.xml
Young adults (aged 15 - 34).
/stats12/gpstab1c
Table-GPS-01-partiii.xml
Youth (15 - 24).
/stats12/gpstab1d
gpstab1d
Table-GPS-01-partiv.xml
gpstab2
Last 12 months prevalence of drug use by age and country, most recent national general population survey available since 2000.
/stats12/gpstab2a
Table-GPS-02-parti.xml
Young adults (15 - 34).
/stats12/gpstab2b
gpstab2b
Table-GPS-02-partii.xml
Youth (aged 15 - 24).
/stats12/gpstab2c
Table-GPS-02-partiii.xml
gpstab3
Last 30 days prevalence of drug use by age and country, most recent national general population survey available since 2000.
/stats12/gpstab3a
Table-GPS-03-parti.xml
/stats12/gpstab3b
Table-GPS-03-partii.xml
/stats12/gpstab3c
Table-GPS-03-partiii.xml
gpstab4
Lifetime prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
All adults male (aged 15 - 64).
/stats12/gpstab4a
gpstab4a
Table-GPS-04-parti.xml
All adults female (aged 15 - 64).
/stats12/gpstab4b
Table-GPS-04-partii.xml
Young adults male (aged 15 - 34).
/stats12/gpstab4c
Table-GPS-04-partiii.xml
Young adults female (aged 15 - 34).
/stats12/gpstab4d
gpstab4d
Table-GPS-04-partiv.xml
Youth male (aged 15 - 24).
/stats12/gpstab4e
gpstab4e
Table-GPS-04-partv.xml
Youth female (aged 15 - 24).
/stats12/gpstab4f
Table-GPS-04-partvi.xml
gpstab5
Last 12 months prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
/stats12/gpstab5a
gpstab5a
Table-GPS-05-parti.xml
/stats12/gpstab5b
Table-GPS-05-partii.xml
/stats12/gpstab5c
Table-GPS-05-partiii.xml
/stats12/gpstab5d
gpstab5d
Table-GPS-05-partiv.xml
/stats12/gpstab5e
gpstab5e
Table-GPS-05-partv.xml
/stats12/gpstab5f
Table-GPS-05-partvi.xml
gpstab6
Last 30 days prevalence of drug use by age, gender and country, most recent national general population survey available since 2000.
/stats12/gpstab6a
gpstab6a
Table-GPS-06-parti.xml
/stats12/gpstab6b
gpstab6b
Table-GPS-06-partii.xml
/stats12/gpstab6c
gpstab6c
Table-GPS-06-partiii.xml
/stats12/gpstab6d
gpstab6d
Table-GPS-06-partiv.xml
/stats12/gpstab6e
Table-GPS-06-partv.xml
/stats12/gpstab6f
Table-GPS-06-partvi.xml
gpstab7
Lifetime prevalence of drug use in all available national general population surveys.
/stats12/gpstab7a
Table-GPS-07-parti.xml
All adults (aged 15 -64).
/stats12/gpstab7b
Table-GPS-07-partii.xml
Young adults (aged 15 -34).
/stats12/gpstab7c
Table-GPS-07-partiii.xml
/stats12/gpstab7d
Table-GPS-07-partiv.xml
gpstab8
Last 12 months prevalence of drug use in all available national general population surveys.
/stats12/gpstab8a
gpstab8a
Table-GPS-08-parti.xml
/stats12/gpstab8b
Table-GPS-08-partii.xml
/stats12/gpstab8c
gpstab8c
Table-GPS-08-partiii.xml
gpstab9
Last 30 days prevalence of drug use in all available national general population surveys.
/stats12/gpstab9a
gpstab9a
Table-GPS-09-parti.xml
/stats12/gpstab9b
Table-GPS-09-partii.xml
/stats12/gpstab9c
Table-GPS-09-partiii.xml
gpstab10
Frequency of use of cannabis amongst users in the last 30 days in national general population surveys.
All adults (aged 15 - 64) - most recent data.
/stats12/gpstab10a
gpstab10a
Table-GPS-10-parti.xml
All adults (aged 15 - 64) - 2007 field trial.
/stats12/gpstab10b
gpstab10b
Table-GPS-10-partii.xml
All adults (aged 15 - 64) - 2004 field trial.
/stats12/gpstab10c
gpstab10c
Table-GPS-10-partiii.xml
Young adults (aged 15 - 34) - combined sources.
/stats12/gpstab10d
gpstab10d
Table-GPS-10-partiv.xml
Methodological information for nation-wide surveys among the general population
/stats12/gpstab121
Table-GPS-121-part0.xml
Last 12 months prevalence of cannabis use among all adults (aged 15 - 64), young adults (aged 15 - 34) and for youth (aged 15 - 24)
/stats12/gpsfig1
Table-GPS-g01-part0.xml
Continuation rates of cannabis use (last 12 months use and last 30 days use as proportions of lifetime use)
/stats12/gpsfig2
Table-GPS-g02-part0.xml
Last 30 days prevalence of cannabis use among youth (aged 15 - 24)
/stats12/gpsfig3
Table-GPS-g03-part0.xml
gpsfig4
Trends in last 12 months prevalence of cannabis use among young adults (aged 15 - 34)
/stats12/gpsfig4a
Table-GPS-g04-parti.xml
Countries with three or more surveys
/stats12/gpsfig4b
gpsfig4b
Table-GPS-g04-partii.xml
Last 12 months prevalence of amphetamines use among young adults (aged 15 - 34) and youth (aged 15 - 24)
/stats12/gpsfig5
Table-GPS-g05-part0.xml
Last 12 months prevalence of amphetamines use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24)
/stats12/gpsfig6
Table-GPS-g06-part0.xml
Last 30 days prevalence of cannabis use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24)
/stats12/gpsfig7
Table-GPS-g07-part0.xml
gpsfig8
Trends in last 12 months use of amphetamines among young adults (aged 15 - 34)
/stats12/gpsfig8a
gpsfig8a
Table-GPS-g08-parti.xml
/stats12/gpsfig8b
Table-GPS-g08-partii.xml
gpsfig9
Last 12 months prevalence of ecstasy use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24)
/stats12/gpsfig9a
Table-GPS-g09-parti.xml
Males aged 15 to 24 in countries with high prevalence rates
/stats12/gpsfig9b
gpsfig9b
Table-GPS-g09-partii.xml
gpsfig10
Last 12 months prevalence of cannabis use by age group in United Kingdom (E&W)
/stats12/gpsfig10
Table-GPS-g10-part0.xml
Continuation rates of ecstasy use (last 12 months use and last 30 days use as proportions of lifetime use)
/stats12/gpsfig11
Table-GPS-g11-part0.xml
gpsfig12
Last 12 months prevalence of cannabis use by age group
Selected EU-15 countries
/stats12/gpsfig12a
gpsfig12a
Table-GPS-g12-parti.xml
Selected 'new' EU countries
/stats12/gpsfig12b
gpsfig12b
Table-GPS-g12-partii.xml
gpsfig13
Last 12 months prevalence of cocaine use among young adults (aged 15 - 34) by gender
/stats12/gpsfig13
Table-GPS-g13-part0.xml
gpsfig14
Trends in last 12 months prevalence of cocaine use among young adults (aged 15 - 34)
/stats12/gpsfig14a
Table-GPS-g14-parti.xml
/stats12/gpsfig14b
Table-GPS-g14-partii.xml
Last 12 months prevalence of cocaine use among all adults (aged 15 - 64), young adults (aged 15 - 34) and youth (aged 15 - 24)
/stats12/gpsfig15
Table-GPS-g15-part0.xml
Continuation rates of cocaine use (last 12 months use and last 30 days use as proportions of lifetime use)
/stats12/gpsfig16
Table-GPS-g16-part0.xml
Last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34)
/stats12/gpsfig17
Table-GPS-g17-part0.xml
gpsfig18
Overview of drug prevalence estimates in Europe for all adults (aged 15 - 64) and young adults (aged 15 - 34)
Cannabis use – lifetime experience, last 12 months and last 30 days prevalence
/stats12/gpsfig18a
gpsfig18a
Table-GPS-g18-parti.xml
Cocaine, amphetamines and ecstasy use – lifetime experience, last 12 months and last 30 days prevalence
/stats12/gpsfig18b
gpsfig18b
Table-GPS-g18-partii.xml
gpsfig20
Lifetime and last 12 months prevalence of cocaine use among young adults (aged 15 - 34) in Europe, Canada, Australia and the USA
/stats12/gpsfig20
Table-GPS-g20-part0.xml
gpsfig21
Trends in last 12 months prevalence of ecstasy use among young adults (aged 15 - 34)
/stats12/gpsfig21a
gpsfig21a
Table-GPS-g21-parti.xml
/stats12/gpsfig21b
gpsfig21b
Table-GPS-g21-partii.xml
Continuation rates of amphetamine use (last 12 months use and last 30 days use as proportions of lifetime use)
/stats12/gpsfig22
Table-GPS-g22-part0.xml
gpsfig23
Trends in last 12 months prevalence of amphetamines, ecstasy and cocaine use among young adults (aged 15 - 34)
/stats12/gpsfig23a
gpsfig23a
Table-GPS-g23-parti.xml
/stats12/gpsfig23b
gpsfig23b
Table-GPS-g23-partii.xml
/stats12/gpsfig23c
gpsfig23c
Table-GPS-g23-partiii.xml
/stats12/gpsfig23d
gpsfig23d
Table-GPS-g23-partiv.xml
/stats12/gpsfig23e
gpsfig23e
Table-GPS-g23-partv.xml
hsrtab1
Year of introduction of methadone maintenance treatment (MMT), high-dosage buprenorphine treatment (HDBT), buprenorphine/naloxone combination, heroin-assisted treatment and slow-release morphine
/stats12/hsrtab1
Table-HSR-01-part0.xml
hsrtab2
Legal framework of opioid substitution treatment initiation, continuation and dispensing (by substitution medication) in EU-27, Croatia, Turkey and Norway
Legal framework regarding the initiation of OST by substitution medication
/stats12/hsrtab2a
Table-HSR-02-parti.xml
Legal framework regarding the continuation of OST by substitution medication
/stats12/hsrtab2b
hsrtab2b
Table-HSR-02-partii.xml
Legal framework regarding the dispensing of substitution medications
/stats12/hsrtab2c
hsrtab2c
Table-HSR-02-partiii.xml
hsrtab3
Estimated number of clients in methadone treatment and of all clients receiving any opioid substitution treatment (OST)
Estimates of clients in methadone treatment or any opioid substitution in EU-27, Croatia, Turkey and Norway, 1993 - 2010
/stats12/hsrtab3a
hsrtab3a
Table-HSR-03-parti.xml
Estimates and share of clients in methadone (MMT) and buprenorphine-based opioid substitution treatment in EU-27, Croatia, Turkey and Norway in 2010 or latest available year
/stats12/hsrtab3b
Table-HSR-03-partii.xml
Methodological notes EU-27, Croatia, Turkey and Norway, 2003 - 2010
/stats12/hsrtab3c
hsrtab3c
Table-HSR-03-partiii.xml
hsrtab4
Year of introduction of needle and syringe programmes (NSPs), types of programmes available in 2010 and number of sites
/stats12/hsrtab4a
Table-HSR-04-parti.xml
NSP geographical coverage, 2010 or latest available year
/stats12/hsrtab4b
hsrtab4b
Table-HSR-04-partii.xml
hsrtab5
Provision of needle and syringe programmes (NSPs)
Syringes provided through needle and syringe programmes (NSPs), 2003-2010
/stats12/hsrtab5a
Table-HSR-05-parti.xml
Clients and contacts at specialist NSP agencies, 2009-2010
/stats12/hsrtab5b
hsrtab5b
Table-HSR-05-partii.xml
hsrtab6
Hepatitis responses in Europe
Hepatitis B immunization in EU27, Croatia, Turkey and Norway
/stats12/hsrtab6a
Table-HSR-06-parti.xml
Hepatitis responses
Availability of Hepatitis C testing in EU27, Croatia, Turkey and Norway
/stats12/hsrtab6b
hsrtab6b
Table-HSR-06-partii.xml
hsrtab7
Availability of selected health responses in prison in EU-27, Croatia, Turkey and Norway
/stats12/hsrtab7
Table-HSR-07-part0.xml
hsrtab8
Responses to drug related deaths in Europe
Availability of selected responses to reduce drug related deaths in 27 EU countries, Norway and Turkey (expert ratings)
/stats12/hsrtab8a
Table-HSR-08-parti.xml
Availability of information material on drug-related deaths and emergencies for specific target groups in 27 EU countries, Norway and Turkey
/stats12/hsrtab8b
hsrtab8b
Table-HSR-08-partii.xml
Opioid substitution treatment in prison in EU 27, Croatia, Turkey and Norway
/stats12/hsrtab9
Table-HSR-09-part0.xml
hsrtab10
Estimation of the total number of clients in treatment in 2010 or latest available year
/stats12/hsrtab10
Table-HSR-10-part0.xml
hsrfig1
Opioid substitution treatment coverage
Opioid substitution treatment clients as a percentage of the estimated number of problem opioid users, 2010 or most recent year available
/stats12/hsrfig1a
Table-HSR-g01-parti.xml
Overall estimated number of problem opioid users in treatment (in opioid substitution treatment and other treatments) as a percentage of the estimated number of problem opioid users, 2010 or most recent year available
/stats12/hsrfig1b
Table-HSR-g01-partii.xml
hsrfig2
Estimated number of clients in opioid substitution treatment (OST) in EU15-12, 1993 - 2010.
/stats12/hsrfig2
Table-HSR-g02-part0.xml
hsrfig3
Syringes distributed through specialised programmes in 2010 per estimated IDU
/stats12/hsrfig3
Table-HSR-g03-part0.xml
hsrfig4
Proportion of prison population receiving opioid substitution treatment (OST) on a given day in 2010 or latest available year
/stats12/hsrfig4
Table-HSR-g04-part0.xml
inftab0
/stats12/inftab0
Table-INF-00-part0.xml
inftab1
Prevalence of HIV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available - Summary table by country
/stats12/inftab1
Table-INF-01-part0.xml
Prevalence of HCV antibody among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available - Summary table by country
/stats12/inftab2
Table-INF-02-part0.xml
Prevalence of markers for HBV infection among injecting drug users in the EU countries, Croatia, Turkey and Norway, 2010 or most recent year available - Summary table by country
/stats12/inftab3
Table-INF-03-part0.xml
inftab104
HIV infections newly diagnosed and AIDS diagnosed among injecting drug users, by country and year of diagnosis
HIV infection in the EU countries, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes
/stats12/inftab104a
inftab104a
Table-INF-104-parti.xml
HIV infection in non-EU countries of the WHO European region: (a) cases per million population, (b) number of cases and (c) population sizes
/stats12/inftab104b
inftab104b
Table-INF-104-partii.xml
AIDS incidence in the EU countries, Croatia, Turkey and Norway: (a) cases per million population, (b) number of cases and (c) population sizes
/stats12/inftab104c
inftab104c
Table-INF-104-partiii.xml
AIDS incidence in non-EU countries of the WHO European region: (a) cases per million population, (b) number of cases and (c) population sizes
/stats12/inftab104d
inftab104d
Table-INF-104-partiv.xml
inftab105
Notified cases of hepatitis C infection among injecting drug users in the EU countries, Croatia and Norway
Total number of cases where transmission route known, number of IDU cases, and percentage of IDUs amongst all cases with known risk factor
/stats12/inftab105a
inftab105a
Table-INF-105-parti.xml
/stats12/inftab105b
inftab105b
Table-INF-105-partii.xml
inftab106
Notified cases of hepatitis B infection among injecting drug users in the EU countries, Croatia and Norway
/stats12/inftab106a
inftab106a
Table-INF-106-parti.xml
/stats12/inftab106b
inftab106b
Table-INF-106-partii.xml
inftab108
Prevalence of HIV infection among injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway
/stats12/inftab108
Table-INF-108-part0.xml
inftab109
Prevalence of HIV infection among injecting drug users under age 25 (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway
/stats12/inftab109
Table-INF-109-part0.xml
inftab110
Prevalence of HIV infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway
/stats12/inftab110
Table-INF-110-part0.xml
inftab111
Prevalence of hepatitis C infection among injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway
/stats12/inftab111
Table-INF-111-part0.xml
inftab112
Prevalence of hepatitis C infection among injecting drug users under age 25 (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway
/stats12/inftab112
Table-INF-112-part0.xml
inftab113
Prevalence of hepatitis C infection among new (injecting less than 2 years) injecting drug users (%), 1991 to 2010. EU countries, Croatia, Turkey and Norway
/stats12/inftab113
Table-INF-113-part0.xml
inftab114
Prevalence of current hepatitis B infection among injecting drug users (% with HBsAg), 1991 to 2010. EU countries, Croatia, Turkey and Norway
/stats12/inftab114
Table-INF-114-part0.xml
inftab115
Prevalence of antibodies against hepatitis B virus among injecting drug users (%), 1991 to 2009. EU countries, Croatia, Turkey and Norway
/stats12/inftab115
Table-INF-115-part0.xml
inffig1
AIDS incidence by year of diagnosis among injecting drug users by country, cases per million 1998 to 2010
EU countries, Croatia, Turkey and Norway
/stats12/inffig1a
inffig1a
Table-INF-g01-parti.xml
Non-EU countries of the WHO European region
/stats12/inffig1b
inffig1b
Table-INF-g01-partii.xml
inffig2
HIV infections newly diagnosed in injecting drug users, cases per million by country and year of diagnosis 2005–2010.
EU countries, Croatia, Turkey and Norway: five highest countries in peak value 2005-2010
/stats12/inffig2a
Table-INF-g02-parti.xml
EU countries, Croatia, Turkey and Norway: countries with 5 to 10 cases per million population in peak value 2005-2010
/stats12/inffig2b
Table-INF-g02-partii.xml
Non-EU countries of WHO European region with over 50 cases per million population in peak value 2005-2010
/stats12/inffig2c
inffig2c
Table-INF-g02-partiii.xml
Non-EU countries of WHO European region with 10 to 50 cases per million population in peak value 2005-2010
/stats12/inffig2d
inffig2d
Table-INF-g02-partiv.xml
inffig3
HIV prevalence among injecting drug users â€” studies with national and subnational coverage
All injecting drug users, 2009 to 2010
/stats12/inffig3a
inffig3a
Table-DRD-g03-partii.xml
Young injecting drug users (under age 25), 2009 to 2010
/stats12/inffig3b
inffig3b
New injecting drug users (injecting less than 2 years), 2009 to 2010
/stats12/inffig3c
inffig3c
inffig6
HCV antibody prevalence among injecting drug users - studies with national and subnational coverage
/stats12/inffig6a
inffig6a
Table-INF-g06-parti.xml
/stats12/inffig6b
inffig6b
/stats12/inffig6c
inffig9
Prevalence of markers of HBV infection among injecting drug users â€” studies with national and subnational coverage
Percentage ever infected (positive for aHBc), 2009 to 2010
/stats12/inffig9a
Table-INF-g09-parti.xml
Prevalence of markers of HBV infection among injecting drug users - studies with national and subnational coverage
Percentage with current infection (positive for HBsAg), 2009 to 2010
/stats12/inffig9b
inffig9b
Table-INF-g09-partii.xml
pdutab0
Estimates of prevalence of problem drug use at national and subnational level: bibliographic references
/stats12/pdutab0
Table-PDU-00-part0.xml
pdutab1
Estimates of prevalence of problem drug use at national level: Summary Table, 2005–2010, rate per 1000 aged 15–64
Overall problem drug use
/stats12/pdutab1a
Table-PDU-01-parti.xml
Estimates of prevalence of problem drug use at national level: Summary Table, 2005-2010, rate per 1000 aged 15–64
/stats12/pdutab1b
pdutab1b
Table-PDU-01-partii.xml
Estimates of prevalence of problem drug use at national level: Summary Table, 2005-2010, rate per 1000 aged 15-64
/stats12/pdutab1c
Table-PDU-01-partiii.xml
pdutab6
Estimated trends in the prevalence of problem and injecting drug use - 2005 to 2010 (rate per 1 000 population aged 15 to 64): Combined estimates per country
Estimated trends of overall problem drug use
/stats12/pdutab6a
Table-PDU-06-parti.xml
Estimated trends in the prevalence of problem and injecting drug use — 2005 to 2010 (rate per 1 000 population aged 15 to 64): Combined estimates per country
Estimated trends of problem opioid use
/stats12/pdutab6b
pdutab6b
Table-PDU-06-partii.xml
Estimated trends of injecting drug use
/stats12/pdutab6c
Table-PDU-06-partiii.xml
Estimated trends of problem stimulant use
/stats12/pdutab6d
Table-PDU-06-partiv.xml
pdutab102
/stats12/pdutab102a
pdutab102a
Table-PDU-102-parti.xml
/stats12/pdutab102b
pdutab102b
Table-PDU-102-partii.xml
pdutab103
/stats12/pdutab103a
pdutab103a
Table-PDU-103-parti.xml
/stats12/pdutab103b
pdutab103b
Table-PDU-103-partii.xml
pdutab104
Trends in injecting drug use - percentage currently injecting among all clients entering treatment for primary drug heroin, 2005 to 2010
/stats12/pdutab104
Table-PDU-104-part0.xml
pdufig1
Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), studies from 2005 to 2010 - last study available
Estimates of overall problem drug use
/stats12/pdufig1a
Table-PDU-g01-parti.xml
Estimates of the prevalence of problem drug use (rate per 1 000 population aged 15 to 64), 2005 to 2010 — last study available
Estimates of problem opioid use
/stats12/pdufig1b
pdufig1b
Table-PDU-g01-partii.xml
/stats12/pdufig2
Table-PDU-g02-part0.xml
ppptab1
Price of cannabis products at retail level, 2010
Minimum, maximum, mean, median and modal price in euros
/stats12/ppptab1a
Table-PPP-01-parti.xml
/stats12/ppptab1b
ppptab1b
Table-PPP-01-partii.xml
/stats12/ppptab1c
Table-PPP-01-partiii.xml
ppptab2
Price of heroin at retail level, 2010
/stats12/ppptab2a
ppptab2a
Table-PPP-02-parti.xml
/stats12/ppptab2b
ppptab2b
Table-PPP-02-partii.xml
/stats12/ppptab2c
Table-PPP-02-partiii.xml
ppptab3
Price of cocaine products at retail level, 2010
/stats12/ppptab3a
ppptab3a
Table-PPP-03-parti.xml
/stats12/ppptab3b
ppptab3b
Table-PPP-03-partii.xml
/stats12/ppptab3c
ppptab3c
Table-PPP-03-partiii.xml
ppptab4
Price of synthetic drugs at retail level, 2010
/stats12/ppptab4a
ppptab4a
Table-PPP-04-parti.xml
/stats12/ppptab4b
ppptab4b
Table-PPP-04-partii.xml
/stats12/ppptab4c
Table-PPP-04-partiii.xml
ppptab5
Potency of cannabis products at retail level, 2010
Minimum, maximum, mean, median and modal potency recorded, measured as percentage of THC content
/stats12/ppptab5a
Table-PPP-05-parti.xml
/stats12/ppptab5b
ppptab5b
Table-PPP-05-partii.xml
Geographical coverage / Sampling frame / Type of study
/stats12/ppptab5c
ppptab5c
Table-PPP-05-partiii.xml
ppptab6
Purity of heroin at retail level, 2010
Minimum, maximum, mean, median and modal purity recorded (percentage)
/stats12/ppptab6a
ppptab6a
Table-PPP-06-parti.xml
/stats12/ppptab6b
ppptab6b
Table-PPP-06-partii.xml
Geographical coverage / Sampling frame / Type of study / Purity determined to base~salt
/stats12/ppptab6c
ppptab6c
Table-PPP-06-partiii.xml
ppptab7
Purity of cocaine products at retail level, 2010
/stats12/ppptab7a
ppptab7a
Table-PPP-07-parti.xml
/stats12/ppptab7b
ppptab7b
Table-PPP-07-partii.xml
/stats12/ppptab7c
ppptab7c
Table-PPP-07-partiii.xml
ppptab8
Purity of synthetic drugs at retail level, 2010
Minimum, maximum, mean, median and modal purity recorded
/stats12/ppptab8a
ppptab8a
Table-PPP-08-parti.xml
/stats12/ppptab8b
ppptab8b
Table-PPP-08-partii.xml
/stats12/ppptab8c
ppptab8c
Table-PPP-08-partiii.xml
ppptab9
Composition of illicit drug tablets, 2010
Content of synthetic scheduled illicit drugs
/stats12/ppptab9a
ppptab9a
Table-PPP-09-parti.xml
/stats12/ppptab9b
ppptab9b
Table-PPP-09-partii.xml
Sampling frame / Type of monitoring system
/stats12/ppptab9c
ppptab9c
Table-PPP-09-partiii.xml
/stats12/ppptab9d
Table-PPP-09-partiv.xml
Information available on adulterants, cutting agents and/or impurities.
/stats12/ppptab9e
ppptab9e
Table-PPP-09-partv.xml
pppfig1
Indexed trends in EU retail prices for major drug types, adjusting for inflation, 2005–10
/stats12/pppfig1
Indexed trends in EU potency/purity for major drug types, adjusting for population size, 2005-2010
/stats12/pppfig2
szrtab0
Data source: name of institution and name of monitoring system/study
/stats12/szrtab0a
szrtab0a
Table-SZR-00-parti.xml
/stats12/szrtab0b
Table-SZR-00-partii.xml
szrtab1
Number of cannabis resin seizures, 1995 to 2010
/stats12/szrtab1
Table-SZR-01-parti.xml
szrtab2
Quantities (kg) of cannabis resin seized, 1995 to 2010
/stats12/szrtab2
Table-SZR-02-parti.xml
szrtab3
Number of herbal cannabis seizures, 1995 to 2010
/stats12/szrtab3
Table-SZR-03-parti.xml
szrtab4
Quantities (kg) of herbal cannabis seized, 1995 to 2010
/stats12/szrtab4
Table-SZR-04-parti.xml
szrtab5
Number of seizures of cannabis plants, 1995 to 2010
/stats12/szrtab5
Table-SZR-05-parti.xml
szrtab6
Quantities (number of plants) of cannabis plants seized, 1995 to 2010
Number of plants, 1995 to 2010
/stats12/szrtab6a
Table-SZR-06-parti.xml
Quantities (Kg) of cannabis plants seized, 1995 to 2010
Quantity (Kg) of plants, 1995 to 2010
/stats12/szrtab6b
szrtab6b
Table-SZR-06-partii.xml
szrtab7
Number of heroin seizures 1995 to 2010
/stats12/szrtab7a
szrtab7a
Table-SZR-07-parti.xml
szrtab8
Quantities (kg) of heroin seized 1995 to 2010
/stats12/szrtab8a
szrtab8a
Table-SZR-08-parti.xml
szrtab9
Number of cocaine seizures 1995 to 2010
/stats12/szrtab9a
szrtab9a
Table-SZR-09-parti.xml
Quantities (kg) of cocaine seized 1995 to 2010
/stats12/szrtab10a
szrtab10a
Table-SZR-10-parti.xml
szrtab11
Number of amphetamine seizures 1995 to 2010
/stats12/szrtab11a
szrtab11a
Table-SZR-11-parti.xml
szrtab12
Quantities (kg) of amphetamine seized 1995 to 2010
Quantities (kg) of amphetamine, 1995 to 2010
/stats12/szrtab12a
szrtab12a
Table-SZR-12-parti.xml
Quantities (tablets) of amphetamine seized 1995 to 2010
Quantity (tablets) of amphetamine, 1995 to 2010
/stats12/szrtab12c
szrtab12c
Table-SZR-12-partiii.xml
szrtab13
Number of ecstasy seizures 1995 to 2010
/stats12/szrtab13a
szrtab13a
Table-SZR-13-parti.xml
szrtab14
Quantities (tablets) of ecstasy seized 1995 to 2010
Quantity (tablets) of ecstasy, 1995 to 2010
/stats12/szrtab14a
Table-SZR-14-parti.xml
Quantities (Kg) of ecstasy seized 1995 to 2010
Quantity (Kg) of ecstasy, 1995 to 2010
/stats12/szrtab14b
szrtab14b
Table-SZR-14-partiii.xml
szrtab15
Number of LSD seizures 1995 to 2010
/stats12/szrtab15
Table-SZR-15-parti.xml
szrtab16
Quantities (units) of LSD seized 1995 to 2010
/stats12/szrtab16
Table-SZR-16-parti.xml
szrtab17
Number of methamphetamine seizures, 2001 to 2010
/stats12/szrtab17
Table-SZR-17-parti.xml
Quantities (kg) of Methamphetamine seized 2001 to 2010
/stats12/szrtab18
Table-SZR-18-parti.xml
szrtab19
Number of crack cocaine seizures, 1995-2010
/stats12/szrtab19
Table-SZR-19-parti.xml
szrtab20
Quantities (kg) of crack cocaine seized 1995 to 2010
/stats12/szrtab20
Table-SZR-20-parti.xml
Other substances seized, 2004 to 2010
Other substances siezed not included in other SZR tables, 2004 to 2010
/stats12/szrtab21a
szrtab21a
Table-SZR-21-parti.xml
szrfig1
Estimated number of heroin seizures and quantities seized (kg) in the EU, Croatia, Turkey and Norway, 2005-2010.
/stats12/szrfig1
Estimated number of cocaine seizures and quantities seized (kg) in the EU, Croatia, Turkey and Norway, 2005-2010.
/stats12/szrfig2
tditab1
Clients entering treatment and treatment units by country, 2010 or most recent year available
/stats12/tditab1
Table-TDI-01-part0.xml
tditab2
Clients entering treatment and reporting treatment units, 1998 to 2010
New clients by country and year of treatment
/stats12/tditab2a
Table-TDI-02-parti.xml
All clients by country and year of treatment
/stats12/tditab2b
Table-TDI-02-partii.xml
Reporting treatment units by country and year of treatment
/stats12/tditab2c
Table-TDI-02-partiii.xml
Types of reporting treatment unit by country
/stats12/tditab2d
Table-TDI-02-partiv.xml
tditab3
New clients entering treatment by primary drug, 1998 to 2010
New heroin clients by country and year of treatment (%)
/stats12/tditab3a
tditab3a
Table-TDI-03-parti.xml
New cocaine clients by country and year of treatment (%)
/stats12/tditab3b
Table-TDI-03-partii.xml
New stimulants (amphetamines and MDMA) clients by country and year of treatment (%)
/stats12/tditab3c
Table-TDI-03-partiii.xml
New cannabis clients by country and year of treatment (%)
/stats12/tditab3d
Table-TDI-03-partiv.xml
tditab4
Demographic characteristics of clients entering treatment, 2010 or most recent year available
New clients by country and gender (%)
/stats12/tditab4a
tditab4a
Table-TDI-04-parti.xml
All clients by country and gender (%)
/stats12/tditab4b
tditab4b
Table-TDI-04-partii.xml
New clients by country and age (%)
/stats12/tditab4c
tditab4c
Table-TDI-04-partiii.xml
All clients by country and age (%)
/stats12/tditab4d
tditab4d
Table-TDI-04-partiv.xml
tditab5
Primary drug and rates of injection of primary drug of clients entering treatment, 2010 or most recent year available
New clients by country and primary drug (%), regardless whether they inject the drug
/stats12/tditab5a
tditab5a
Table-TDI-05-parti.xml
All clients by country and primary drug (%), regardless whether they inject the drug
/stats12/tditab5b
tditab5b
Table-TDI-05-partii.xml
New clients by country and rates of injection of primary drug (%)
/stats12/tditab5c
tditab5c
Table-TDI-05-partiii.xml
All clients by country and rates of injection of primary drug (%)
/stats12/tditab5d
Table-TDI-05-partiv.xml
tditab6
Incidence of treatment demand for drug use, 2010 or most recent year available. New clients by country (rate per 100 000 population aged 15 to 64 years old)
/stats12/tditab6
Table-TDI-06-part0.xml
tditab7
Data coverage, 2010 or most recent year available
Clients entering treatment by country and type of treatment centre and type of client
/stats12/tditab7a
tditab7a
Table-TDI-07-parti.xml
Units by country and type of treatment centre and reporting status
/stats12/tditab7b
tditab7b
Table-TDI-07-partii.xml
tditab8
Primary use of stimulants of clients entering treatment, 2010 or most recent year available
New clients by country and type of stimulant (%)
/stats12/tditab8a
tditab8a
Table-TDI-08-parti.xml
All clients by country and type of stimulant (%)
/stats12/tditab8b
tditab8b
Table-TDI-08-partii.xml
tditab9
Demographic characteristics of clients entering outpatient treatment, 2010 or most recent year available
New outpatient clients by country and gender
/stats12/tditab9a
tditab9a
Table-TDI-09-parti.xml
All outpatient clients by country and gender
/stats12/tditab9b
tditab9b
Table-TDI-09-partii.xml
New outpatient clients by country and age
/stats12/tditab9c
tditab9c
Table-TDI-09-partiii.xml
All outpatient clients by country and age
/stats12/tditab9d
tditab9d
Table-TDI-09-partiv.xml
tditab10
Age distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
New outpatient clients, age distribution by primary drug (%)
/stats12/tditab10a
tditab10a
Table-TDI-10-parti.xml
New outpatient clients, primary drug distribution by age (%)
/stats12/tditab10b
tditab10b
Table-TDI-10-partii.xml
All outpatient clients, age distribution by primary drug (%)
/stats12/tditab10c
tditab10c
Table-TDI-10-partiii.xml
All outpatient clients, primary drug distribution by age (%)
/stats12/tditab10d
tditab10d
Table-TDI-10-partiv.xml
New inpatient clients, age distribution by primary drug (%)
/stats12/tditab10e
tditab10e
Table-TDI-10-partv.xml
New inpatient clients, primary drug distribution by age (%)
/stats12/tditab10f
tditab10f
Table-TDI-10-partvi.xml
All inpatient clients, age distribution by primary drug (%)
/stats12/tditab10g
tditab10g
Table-TDI-10-partvii.xml
All inpatient clients, primary drug distribution by age (%)
/stats12/tditab10h
tditab10h
Table-TDI-10-partviii.xml
tditab11
Age at first use distributions and primary drug distributions — EU summary of clients entering treatment, 2010 or most recent year available
New outpatient clients, age at first use distribution by primary drug (%)
/stats12/tditab11a
tditab11a
Table-TDI-11-parti.xml
New outpatient clients, primary drug distribution by age at first use (%)
/stats12/tditab11b
tditab11b
Table-TDI-11-partii.xml
All outpatient clients, age at first use distribution by primary drug (%)
/stats12/tditab11c
tditab11c
Table-TDI-11-partiii.xml
All outpatient clients, primary drug distribution by age at first use (%)
/stats12/tditab11d
tditab11d
Table-TDI-11-partiv.xml
New inpatient clients, age at first use distribution by primary drug (%)
/stats12/tditab11e
tditab11e
Table-TDI-11-partv.xml
New inpatient clients, primary drug distribution by age at first use (%)
/stats12/tditab11f
tditab11f
Table-TDI-11-partvi.xml
All inpatient clients, age at first use distribution by primary drug (%)
/stats12/tditab11g
tditab11g
Table-TDI-11-partvii.xml
All inpatient clients, primary drug distribution by age at first use (%)
/stats12/tditab11h
tditab11h
Table-TDI-11-partviii.xml
tditab12
Education status of clients entering treatment, 2010 or most recent year available
New outpatient clients by country and education status (%)
/stats12/tditab12a
Table-TDI-12-parti.xml
All outpatient clients by country and education status (%)
/stats12/tditab12b
tditab12b
Table-TDI-12-partii.xml
New inpatient clients by country and education status (%)
/stats12/tditab12c
tditab12c
Table-TDI-12-partiii.xml
All inpatient clients by country and education status (%)
/stats12/tditab12d
tditab12d
Table-TDI-12-partiv.xml
tditab13
Labour status of clients entering treatment, 2010 or most recent year available
New outpatient clients by country and labour status (%)
/stats12/tditab13a
Table-TDI-13-parti.xml
All outpatient clients by country and labour status (%)
/stats12/tditab13b
tditab13b
Table-TDI-13-partii.xml
New inpatient clients by country and labour status (%)
/stats12/tditab13c
tditab13c
Table-TDI-13-partiii.xml
All inpatient clients by country and labour status (%)
/stats12/tditab13d
tditab13d
Table-TDI-13-partiv.xml
tditab14
Persons with whom client is living on entering treatment, 2010 or most recent year available
New outpatient clients by country and with whom living (%)
/stats12/tditab14a
tditab14a
Table-TDI-14-parti.xml
All outpatient clients by country and with whom living (%)
/stats12/tditab14b
tditab14b
Table-TDI-14-partii.xml
New inpatient clients by country and with whom living (%)
/stats12/tditab14c
tditab14c
Table-TDI-14-partiii.xml
All inpatient clients by country and with whom living (%)
/stats12/tditab14d
tditab14d
Table-TDI-14-partiv.xml
tditab15
Type of accommodation of clients entering treatment, 2010 or most recent year available
New clients entering outpatient treatment by country and type of accommodation (%)
/stats12/tditab15a
Table-TDI-15-parti.xml
All clients entering outpatient treatment by country and type of accommodation (%)
/stats12/tditab15b
Table-TDI-15-partii.xml
New clients entering inpatient treatment by country and type of accommodation (%)
/stats12/tditab15c
tditab15c
Table-TDI-15-partiii.xml
All clients entering inpatient treatment by country and type of accommodation (%)
/stats12/tditab15d
tditab15d
Table-TDI-15-partiv.xml
tditab16
Source of referral of clients entering treatment, 2010 or most recent year available
New outpatient clients by country and source of referral (%)
/stats12/tditab16a
tditab16a
Table-TDI-16-parti.xml
All outpatient clients by country and source of referral (%)
/stats12/tditab16b
tditab16b
Table-TDI-16-partii.xml
New inpatient clients by country and source of referral (%)
/stats12/tditab16c
tditab16c
Table-TDI-16-partiii.xml
All inpatient clients by country and source of referral (%)
/stats12/tditab16d
tditab16d
Table-TDI-16-partiv.xml
tditab17
Route of administration by primary drug of clients entering treatment, 2010 or most recent year available
New opioid outpatient clients by country and usual route of administration (%)
/stats12/tditab17a
tditab17a
Table-TDI-17-parti.xml
All opioid outpatient clients by country and usual route of administration (%)
/stats12/tditab17b
tditab17b
Table-TDI-17-partii.xml
New cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
/stats12/tditab17c
Table-TDI-17-partiii.xml
All cocaine (HCl and crack) outpatient clients by country and usual route of administration (%)
/stats12/tditab17d
Table-TDI-17-partiv.xml
New cannabis outpatient clients by country and usual route of administration (%)
/stats12/tditab17i
Table-TDI-17-partix.xml
New stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
/stats12/tditab17e
tditab17e
Table-TDI-17-partv.xml
All stimulants (other than cocaine) outpatient clients by country and usual route of administration (%)
/stats12/tditab17f
Table-TDI-17-partvi.xml
New hypnotics and sedatives outpatient clients by country and usual route of administration (%)
/stats12/tditab17g
tditab17g
Table-TDI-17-partvii.xml
All hypnotics and sedatives outpatient clients by country and usual route of administration (%)
/stats12/tditab17h
tditab17h
Table-TDI-17-partviii.xml
All cannabis outpatient clients by country and usual route of administration (%)
/stats12/tditab17j
tditab17j
Table-TDI-17-partx.xml
tditab18
Frequency of use of primary drug of clients entering treatment, 2010 or most recent year available
New outpatient clients by primary drug and frequency of use (%)
/stats12/tditab18a
tditab18a
Table-TDI-18-parti.xml
All outpatient clients by primary drug and frequency of use (%)
/stats12/tditab18b
tditab18b
Table-TDI-18-partii.xml
New inpatient clients by primary drug and frequency of use (%)
/stats12/tditab18c
tditab18c
Table-TDI-18-partiii.xml
All inpatient clients by primary drug and frequency of use (%)
/stats12/tditab18d
tditab18d
Table-TDI-18-partiv.xml
tditab19
Primary drug of clients entering treatment, 2010 or most recent year available
New outpatient clients by country and primary drug (%)
/stats12/tditab19a
tditab19a
Table-TDI-19-parti.xml
All outpatient clients by country and primary drug (%)
/stats12/tditab19b
tditab19b
Table-TDI-19-partii.xml
New inpatient clients by country and primary drug (%)
/stats12/tditab19c
tditab19c
Table-TDI-19-partiii.xml
All inpatient clients by country and primary drug (%)
/stats12/tditab19d
tditab19d
Table-TDI-19-partiv.xml
tditab21
Gender ratio by primary drug of clients entering treatment, 2010 or most recent year available
New outpatient clients, ratio of males to females by country and primary drug
/stats12/tditab21a
Table-TDI-21-parti.xml
All outpatient clients, ratio of males to females by country and primary drug
/stats12/tditab21b
Table-TDI-21-partii.xml
New inpatient clients, ratio of males to females by country and primary drug
/stats12/tditab21c
Table-TDI-21-partiii.xml
All inpatient clients, ratio of males to females by country and primary drug
/stats12/tditab21d
Table-TDI-21-partiv.xml
tditab22
Secondary drugs cited by clients entering treatment, 2010 or most recent year available
/stats12/tditab22a
tditab22a
Table-TDI-22-parti.xml
/stats12/tditab22b
tditab22b
Table-TDI-22-partii.xml
tditab24
Type of treatment centre by primary drug of clients entering treatment, 2010 or most recent year available
New clients by country and primary drug and type of treatment centre (%)
/stats12/tditab24a
tditab24a
Table-TDI-24-parti.xml
All clients by country and primary drug and type of treatment centre (%)
/stats12/tditab24b
Table-TDI-24-partii.xml
tditab25
Age distribution of all clients entering outpatient treatment by primary drug and gender, 2010 or most recent year available
/stats12/tditab25
Table-TDI-25-part0.xml
tditab32
Mean age of clients entering treatment by primary drug and gender, 2010 or most recent year available
/stats12/tditab32a
tditab32a
Table-TDI-32-parti.xml
/stats12/tditab32b
tditab32b
Table-TDI-32-partii.xml
tditab33
Mean age at first use and mean age at entering treatment by gender and primary drug among new clients entering treatment, 2010 or most recent year available
/stats12/tditab33a
tditab33a
Table-TDI-33-parti.xml
/stats12/tditab33b
tditab33b
Table-TDI-33-partii.xml
tditab36
Primary amphetamine use among new clients entering treatment (%), 2005 to 2010
/stats12/tditab36
Table-TDI-36-part0.xml
tditab37
Amphetamines and ecstasy clients entering drug treatment, 2010 or most recent year available
All clients by country and primary drug and type of treatment unit
/stats12/tditab37a
tditab37a
Table-TDI-37-parti.xml
Outpatient clients by primary drug and mean age, gender ratio
/stats12/tditab37b
tditab37b
Table-TDI-37-partii.xml
Inpatient clients by primary drug and mean age, gender ratio
/stats12/tditab37c
tditab37c
Table-TDI-37-partiii.xml
Outpatient clients by secondary drug and primary drug
/stats12/tditab37d
tditab37d
Table-TDI-37-partiv.xml
Inpatient clients by secondary drug and primary drug
/stats12/tditab37e
tditab37e
Table-TDI-37-partv.xml
tditab102
New clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
New opioid outpatient clients by country and age
/stats12/tditab102a
tditab102a
Table-TDI-102-parti.xml
New cocaine (HCI and 'crack') outpatient clients by country and age
/stats12/tditab102b
Table-TDI-102-partii.xml
New stimulants (other than cocaine) outpatient clients by country and age
/stats12/tditab102c
Table-TDI-102-partiii.xml
New hallucinogen outpatient clients by country and age
/stats12/tditab102d
tditab102d
Table-TDI-102-partiv.xml
New hypnotics and sedatives outpatient clients by country and age
/stats12/tditab102e
Table-TDI-102-partv.xml
New volatile inhalant outpatient clients by country and age
/stats12/tditab102f
tditab102f
Table-TDI-102-partvi.xml
New cannabis outpatient clients by country and age
/stats12/tditab102g
tditab102g
Table-TDI-102-partvii.xml
New 'other drugs' outpatient clients by country and by age
/stats12/tditab102h
tditab102h
Table-TDI-102-partviii.xml
tditab103
All clients entering outpatient treatment by primary drug and age, 2010 or most recent year available
All opioid outpatient clients by country and age
/stats12/tditab103a
tditab103a
Table-TDI-103-parti.xml
All cocaine (HCI and 'crack') outpatient clients by country and age
/stats12/tditab103b
Table-TDI-103-partii.xml
All stimulants (other than cocaine) outpatient clients by country and age
/stats12/tditab103c
Table-TDI-103-partiii.xml
All hallucinogen outpatient clients by country and age
/stats12/tditab103d
tditab103d
Table-TDI-103-partiv.xml
All hypnotics and sedatives outpatient clients by country and age
/stats12/tditab103e
Table-TDI-103-partv.xml
All volatile inhalant outpatient clients by country and age
/stats12/tditab103f
tditab103f
Table-TDI-103-partvi.xml
All cannabis outpatient clients by country and age
/stats12/tditab103g
tditab103g
Table-TDI-103-partvii.xml
All 'other drugs' outpatient clients by country and by age
/stats12/tditab103h
tditab103h
Table-TDI-103-partviii.xml
tditab104
New clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
New opioid inpatient clients by country and age
/stats12/tditab104a
tditab104a
Table-TDI-104-parti.xml
New cocaine (HCI and 'crack') inpatient clients by country and age
/stats12/tditab104b
Table-TDI-104-partii.xml
New stimulants (other than cocaine) inpatient clients by country and age
/stats12/tditab104c
Table-TDI-104-partiii.xml
New hallucinogen inpatient clients by country and age
/stats12/tditab104d
tditab104d
Table-TDI-104-partiv.xml
New hypnotics and sedatives inpatient clients by country and age
/stats12/tditab104e
tditab104e
Table-TDI-104-partv.xml
New volatile inhalant inpatient clients by country and age
/stats12/tditab104f
tditab104f
Table-TDI-104-partvi.xml
New cannabis inpatient clients by country and age
/stats12/tditab104g
tditab104g
Table-TDI-104-partvii.xml
New 'other drugs' inpatient clients by country and by age
/stats12/tditab104h
tditab104h
Table-TDI-104-partviii.xml
tditab105
All clients entering inpatient treatment by primary drug and age, 2010 or most recent year available
All opioid inpatient clients by country and age
/stats12/tditab105a
tditab105a
Table-TDI-105-parti.xml
All cocaine (HCI and 'crack') inpatient clients by country and age
/stats12/tditab105b
Table-TDI-105-partii.xml
All stimulants (other than cocaine) inpatient clients by country and age
/stats12/tditab105c
Table-TDI-105-partiii.xml
All hallucinogen inpatient clients by country and age
/stats12/tditab105d
tditab105d
Table-TDI-105-partiv.xml
All hypnotics and sedatives inpatient clients by country and age
/stats12/tditab105e
Table-TDI-105-partv.xml
All volatile inhalant inpatient clients by country and age
/stats12/tditab105f
tditab105f
Table-TDI-105-partvi.xml
All cannabis inpatient clients by country and age
/stats12/tditab105g
tditab105g
Table-TDI-105-partvii.xml
All 'other drugs' inpatient clients by country and by age
/stats12/tditab105h
tditab105h
Table-TDI-105-partviii.xml
tditab106
New clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
New opioid outpatient clients by country and age at first use
/stats12/tditab106a
tditab106a
Table-TDI-106-parti.xml
New cocaine (HCI and 'crack') outpatient clients by country and age at first use
/stats12/tditab106b
Table-TDI-106-partii.xml
New stimulants (other than cocaine) outpatient clients by country and age at first use
/stats12/tditab106c
Table-TDI-106-partiii.xml
New hallucinogen outpatient clients by country and age at first use
/stats12/tditab106d
Table-TDI-106-partiv.xml
New hypnotics and sedatives outpatient clients by country and age at first use
/stats12/tditab106e
tditab106e
Table-TDI-106-partv.xml
New volatile inhalant outpatient clients by country and age at first use
/stats12/tditab106f
Table-TDI-106-partvi.xml
New cannabis outpatient clients by country and age at first use
/stats12/tditab106g
tditab106g
Table-TDI-106-partvii.xml
New 'other drugs' outpatient clients by country and by age at first use
/stats12/tditab106h
tditab106h
Table-TDI-106-partviii.xml
tditab107
All clients entering outpatient treatment by primary drug and age at first use, 2010 or most recent year available
All opioid outpatient clients by country and age at first use
/stats12/tditab107a
Table-TDI-107-parti.xml
All cocaine (HCI and 'crack') outpatient clients by country and age at first use
/stats12/tditab107b
tditab107b
Table-TDI-107-partii.xml
All stimulants (other than cocaine) outpatient clients by country and age at first use
/stats12/tditab107c
tditab107c
Table-TDI-107-partiii.xml
All hallucinogen outpatient clients by country and age at first use
/stats12/tditab107d
Table-TDI-107-partiv.xml
All hypnotics and sedatives outpatient clients by country and age at first use
/stats12/tditab107e
Table-TDI-107-partv.xml
All volatile inhalant outpatient clients by country and age at first use
/stats12/tditab107f
Table-TDI-107-partvi.xml
All cannabis outpatient clients by country and by age at first use
/stats12/tditab107g
Table-TDI-107-partvii.xml
All 'other drugs' outpatient clients by country and by age at first use
/stats12/tditab107h
Table-TDI-107-partviii.xml
tditab108
New clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
New opioid inpatient clients by country and age at first use
/stats12/tditab108a
tditab108a
Table-TDI-108-parti.xml
New cocaine (HCI and 'crack') inpatient clients by country and age at first use
/stats12/tditab108b
tditab108b
Table-TDI-108-partii.xml
New stimulants (other than cocaine) inpatient clients by country and age at first use
/stats12/tditab108c
tditab108c
Table-TDI-108-partiii.xml
New hallucinogen inpatient clients by country and age at first use
/stats12/tditab108d
tditab108d
Table-TDI-108-partiv.xml
New hypnotics and sedatives inpatient clients by country and age at first use
/stats12/tditab108e
tditab108e
Table-TDI-108-partv.xml
New volatile inhalant inpatient clients by country and age at first use
/stats12/tditab108f
tditab108f
Table-TDI-108-partvi.xml
New cannabis inpatient clients by country and age at first use
/stats12/tditab108g
tditab108g
Table-TDI-108-partvii.xml
New 'other drugs' inpatient clients by country and age at first use
/stats12/tditab108h
tditab108h
Table-TDI-108-partviii.xml
tditab109
All clients entering inpatient treatment by primary drug and age at first use, 2010 or most recent year available
All opioid inpatient clients by country and age at first use
/stats12/tditab109a
tditab109a
Table-TDI-109-parti.xml
All cocaine (HCI and 'crack') inpatient clients by country and age at first use
/stats12/tditab109b
tditab109b
Table-TDI-109-partii.xml
All stimulants (other than cocaine) inpatient clients by country and age at first use
/stats12/tditab109c
tditab109c
Table-TDI-109-partiii.xml
All hallucinogen inpatient clients by country and age at first use
/stats12/tditab109d
tditab109d
Table-TDI-109-partiv.xml
All hypnotics and sedatives inpatient clients by country and age at first use
/stats12/tditab109e
tditab109e
Table-TDI-109-partv.xml
All volatile inhalant inpatient clients by country and age at first use
/stats12/tditab109f
tditab109f
Table-TDI-109-partvi.xml
All cannabis inpatient clients by country and age at first use
/stats12/tditab109g
tditab109g
Table-TDI-109-partvii.xml
All 'other drugs' inpatient clients by country and by age at first use
/stats12/tditab109h
tditab109h
Table-TDI-109-partviii.xml
tditab111
Frequency of use of primary drug of clients entering outpatient treatment, 2010 or most recent year available
New opioid outpatient clients by country and frequency of use (%)
/stats12/tditab111a
Table-TDI-111-parti.xml
All opioid outpatient clients by country and frequency of use (%)
/stats12/tditab111b
Table-TDI-111-partii.xml
New cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
/stats12/tditab111c
tditab111c
Table-TDI-111-partiii.xml
All cocaine (HCI and ‘crack’) outpatient clients by country and frequency of use (%)
/stats12/tditab111d
Table-TDI-111-partiv.xml
New stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
/stats12/tditab111e
tditab111e
Table-TDI-111-partv.xml
All stimulants (other than cocaine) outpatient clients by country and frequency of use (%)
/stats12/tditab111f
Table-TDI-111-partvi.xml
New cannabis outpatient clients by country and frequency of use (%)
/stats12/tditab111g
Table-TDI-111-partvii.xml
All cannabis outpatient clients by country and frequency of use (%)
/stats12/tditab111h
tditab111h
Table-TDI-111-partviii.xml
tditab112
Frequency of use of primary drug of clients entering inpatient treatment, 2010 or most recent year available
New opioid inpatient clients by country and frequency of use (%)
/stats12/tditab112a
tditab112a
Table-TDI-112-parti.xml
All opioid inpatient clients by country and frequency of use (%)
/stats12/tditab112b
tditab112b
Table-TDI-112-partii.xml
New cannabis inpatient clients by country and frequency of use (%)
/stats12/tditab112c
tditab112c
Table-TDI-112-partiii.xml
All cannabis inpatient clients by country and frequency of use (%)
/stats12/tditab112d
tditab112d
Table-TDI-112-partiv.xml
New stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
/stats12/tditab112e
tditab112e
Table-TDI-112-partv.xml
All stimulants (other than cocaine) inpatient clients by country and frequency of use (%)
/stats12/tditab112f
tditab112f
Table-TDI-112-partvi.xml
New cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
/stats12/tditab112g
tditab112g
Table-TDI-112-partvii.xml
All cocaine (HCI and ‘crack’) inpatient clients by country and frequency of use (%)
/stats12/tditab112h
tditab112h
Table-TDI-112-partviii.xml
tditab113
All clients entering treatment for opioids by country and type of opioid misused (%), 2010 or most recent year available
/stats12/tditab113
Table-TDI-113-part0.xml
tditab114
Primary opioids distribution among all clients entering treatment by country and type of treatment centre (%), 2010
/stats12/tditab114
Table-TDI-114-part0.xml
tditab115
HCL and Crack use of clients entering outpatient treatment , 2010 or most recent year available
New outpatient clients by country and type of cocaine product
/stats12/tditab115a
tditab115a
Table-TDI-115-parti.xml
All outpatient clients by country and type of cocaine product
/stats12/tditab115b
tditab115b
Table-TDI-115-partii.xml
tdifig1
Trend in estimated number of new clients entering treatment by selected primary drugs, 2005 to 2010
Percentage by primary drug
/stats12/tdifig1a
Table-TDI-g01-parti.xml
Trend in estimated number of new clients entering treatment by primary drug used, from 2005 to 2010
Numbers of clients by primary drug
/stats12/tdifig1b
tdifig1b
Table-TDI-g01-partii.xml
tdifig2
New and all clients entering treatment by primary drug: heroin, cocaine, cannabis, other stimulants and other drugs in 2010.
/stats12/tdifig2a
tdifig2a
Table-TDI-g02-parti.xml
/stats12/tdifig2b
tdifig2b
Table-TDI-g02-partii.xml
tdifig3
Trend in estimated number of all clients entering treatment by selected primary drug used, 2005 to 2010
/stats12/tdifig3a
tdifig3a
Table-TDI-g03-parti.xml
Trend in estimated number of all clients entering treatment by selected primary drugs, 2005 to 2010
/stats12/tdifig3b
Table-TDI-g03-partii.xml
tdifig7
New outpatient clients injecting opioid as primary drug from 2005 to 2010 in 18 countries supplying data
/stats12/tdifig7
Table-TDI-g07-part0.xml
About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is the reference point on drugs and drug addiction information in Europe. Inaugurated in Lisbon in 1995, it is one of the EU's decentralised agencies. Read more >> Contact us EMCDDA Praça Europa 1, Cais do Sodré 1249-289 Lisbon Portugal Tel. (351) 211 21 02 00 Fax (351) 218 13 17 11 More contact options >> Quick links Annual report Events Press room Vacancies Partners FAQ Legal notice Site map Follow us Twitter Facebook Flickr YouTube RSS Newsletter Page last updated: Friday, 19 December 2014